Form 8-K - Current report:
SEC Accession No. 0001193125-24-180349
Filing Date
2024-07-17
Accepted
2024-07-17 16:04:02
Documents
14
Period of Report
2024-07-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d807476d8k.htm   iXBRL 8-K 32314
2 EX-10.1 d807476dex101.htm EX-10.1 89554
  Complete submission text file 0001193125-24-180349.txt   277969

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pkbo-20240712.xsd EX-101.SCH 2500
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE pkbo-20240712_lab.xml EX-101.LAB 18700
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pkbo-20240712_pre.xml EX-101.PRE 11677
17 EXTRACTED XBRL INSTANCE DOCUMENT d807476d8k_htm.xml XML 3883
Mailing Address 4900 HOPYARD ROAD, SUITE 100 PLEASANTON CA 94588
Business Address 4900 HOPYARD ROAD, SUITE 100 PLEASANTON CA 94588 (925) 463-4800
Peak Bio, Inc. (Filer) CIK: 0001834645 (see all company filings)

EIN.: 852448157 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39951 | Film No.: 241122210
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)